MediWound Ltd. (NASDAQ:MDWD) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET
Company Participants
Gaia Shamis - IR, LifeSci Advisors
Ofer Gonen - Chief Executive Officer
Hani Luxenburg - Chief Financial Officer
Barry Wolfenson - EVP of Strategy & Corporate Development
Conference Call Participants
Joshua Jennings - TD Cowen
Swayampakula Ramakanth - HC Wainwright
Michael Okunewitch - Maxim Group
Operator
Good day and welcome to MediWound's Second Quarter 2024 Earnings Call. Today's conference is being recorded. [Operator Instructions] At this time, I would like to turn the conference over to Gaia Shamis of LifeSci Advisors. Please go ahead.
Gaia Shamis
Thank you, Chris, and welcome, everyone. Today, before the market opened, MediWound issued a press release announcing financial results for the second quarter ended June 30, 2024. You may access that release on the company's website under the Investors tab. With us today are Ofer Gonen, Chief Executive Officer of MediWound; Hani Luxenburg, Chief Financial Officer; and Barry Wolfenson, Executive Vice President of Strategy and Corporate Development. Following our prepared remarks, we will open the call for Q&A.
Before we begin, I would like to remind everyone that statements made during this call including the Q&A session relating to MediWound's expected future performance, future business prospects or future events or plans are forward-looking statements and defined under the Private Securities Litigation Reform Act of 1995. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties and could differ materially from those forecast due to the impact of many factors beyond the control of MediWound.
The company assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events or otherwise. Participants are directed to cautionary notes set forth in today's press release as well as the risk factors set forth in MediWound's annual report filed with the SEC for factors that could cause actual results to differ materially from those anticipated in the forward-looking statements. The conference call is the property of MediWound, and any recording or rebroadcast is expressly prohibited without the written consent of MediWound. Now I would like to turn the call over to Ofer Gonen, Chief Executive Officer of MediWound. Ofer?
Ofer Gonen
Thank you, Gaia, and good morning, everyone. We appreciate you joining us today as we are excited to share the results of another strong quarter. The second quarter has been pivotal for our company, as we continue to execute our strategic plan to become a global leader in tissue repair. At the beginning of the year, we set three key goals: